European Academy of Allergy and Clinical Immunology guidance during COVID-19

Gary Hodgson, Medicines Information Pharmacist, North West Medicines Information CentrePublished Last updated See all updates

Links to allergy-related statements and journal articles in the context of COVID-19.

Background

The European Academy of Allergy and Clinical Immunology (EAACI) COVID-19 Resource Centre links to relevant documents.

Links provided to documents, including:

  • EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines.
  • Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – A statement from the EAACI-Section on Pediatrics.

In addition there is a Statement on intra-nasal corticosteroids that advises:

  • With current knowledge, intra-nasal corticosteroid sprays can be continued in allergic rhinitis and during the pollen season at recommended doses.
  • Stopping local intra-nasal corticosteroid sprays is not advised as immunosuppression has not been proven; moreover, stopping may lead to increased sneezing, which could lead to spreading of the coronavirus.
  • Moreover; unnecessary SARS-COV 2 testing and doctor’s visits may be avoided by sufficient treatment of allergic airway problems; since patients may confound allergic induced nasal symptoms and cough with signs of virus infection.

Change history

  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Published